• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

non-small cell lung cancer (NSCLC) - Articles and news items

Novartis receives positive CHMP opinion for lung cancer combination

Industry news / 27 February 2017 / Niamh Marriott, Digital Editor

The EMA approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) to treat patients with non-small cell lung cancer…

Novartis’ NSCLC study shows 16.6 month progression-free survival

Industry news / 12 December 2016 / Niamh Louise Marriott, Digital Editor

Patients with ALK+ advanced non-small cell lung cancer treated with Zykadia had a median progression-free survival of 16.6 months, compared to placebo…

FDA approves Roche’s immunotherapy assay to support treatment decisions in lung cancer

Industry news / 31 October 2016 / Niamh Louise Marriott, Digital Content Producer

The US Food and Drug Administration (FDA) has approved Roche’s PD-L1 assay as a diagnostic to identify PD-L1 expression levels in patients considering treatment with Tecentriq (atezolizumab) for previously treated metastatic non-small cell lung cancer (NSCLC). The PD-L1 (SP142) assay is also indicated to identify patients with urothelial cancer (UC) who may benefit from treatment […]

OncoGenex’s Phase 3 non-small cell lung cancer trial did not meet primary endpoint

Industry news / 14 October 2016 / Niamh Louise Marriott, Digital Content Producer

OncoGenex’ results, analysed from the Phase 3 trial of custirsen in patients whose non-small cell lung cancer (NSCLC) has progressed following initial…

NICE says CDF case for nivolumab to treat lung cancer is not clear cut

Industry news / 14 October 2016 / Niamh Louise Marriott, Digital Content Producer

NICE’s appraisal committee concluded that nivolumab was not cost-effective for all patients in the treatment of non small-cell lung cancer…

Scancell preparing SCIB2 for clinical study in lung cancer

Industry news / 13 October 2016 / Niamh Louise Marriott, Digital Content Producer

Scancell intends to develop its SCIB2 ImmunoBody for the treatment of non-small cell lung cancer (NSCLC) in combination with a checkpoint inhibitor…

Scotland speeds ahead to deliver breakthrough immunotherapy to lung cancer patients 

Industry news / 11 October 2016 / Niamh Louise Marriott, Digital Content Producer

This recommendation means that patients in Scotland will become the first in the UK to be treated with nivolumab on the NHS…

 

Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringWATCH NOW
+ +